Elevation Oncology(ELEV) - 2023 Q4 - Annual Results

Boston, Mass. March 6, 2024 – Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter and full-year ended December 31, 2023, and highlighted recent business achievements. "We are entering 2024 with tremendous momentum across our pipeline of differentiated ADC therapies," said Joseph Ferr ...